CDKN2A and melanoma: All of the pathways shown in Table 1, Table 2 and Table 3 (adapted from Edler et al.)have an ‘intermediate’ category of lesions that have one or a few progression-related genomic changes (such as hemizygous loss of CDKN2A or a TERT promoter mutation) but insufficient to become melanoma [10].